CRV-101 is an investigational adjuvanted subunit vaccine for the indication of prevention of Herpes Zoster in older adults. As next-generation Herpes Zoster subunit vaccine, CRV-101 is designed to maximize the cell-mediated immunity response by combining the gE protein antigen with Th1-biased adjuvant.
In collaboration with GC Pharma, MOGAM licensed out CRV-101 to Curevo Vaccine. The phase I clinical trial for CRV-101 was conducted to evaluate the safety, tolerability, and immunogenicity in healthy adult subjects.

Curevo Vaccine is a clinical-stage biotechnology company dedicated to developing next generation adjuvanted subunit vaccines for patients with infectious disease of global health importance. Headquartered in Seattle, Washington, Curevo Vaccine combines excellence in protein and adjuvant biology to create vaccines. Curevo Vaccine is currently conducting clinical development on CRV-101